#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=4 .
1-1	0-1	4	quantity	new	_	_
1-2	2-3	.	_	_	_	_

#Text=Discussion
2-1	4-14	Discussion	abstract	new	_	_

#Text=Here , we describe a link between fructose and NO levels in the NTS , as well as its association with baroreflex sensitivity and activation of the CNS .
3-1	15-19	Here	_	_	_	_
3-2	20-21	,	_	_	_	_
3-3	22-24	we	person	acc	ana	4-1
3-4	25-33	describe	_	_	_	_
3-5	34-35	a	abstract[4]	new[4]	ana	3-19[0_4]
3-6	36-40	link	abstract[4]	new[4]	_	_
3-7	41-48	between	abstract[4]	new[4]	_	_
3-8	49-57	fructose	abstract[4]|substance	new[4]|new	coref	4-6
3-9	58-61	and	abstract[4]	new[4]	_	_
3-10	62-64	NO	abstract[4]|abstract[6]	new[4]|new[6]	coref	5-5[28_6]
3-11	65-71	levels	abstract[4]|abstract[6]	new[4]|new[6]	_	_
3-12	72-74	in	abstract[4]|abstract[6]	new[4]|new[6]	_	_
3-13	75-78	the	abstract[4]|abstract[6]|object[7]	new[4]|new[6]|new[7]	coref	27-13[204_7]
3-14	79-82	NTS	abstract[4]|abstract[6]|object[7]	new[4]|new[6]|new[7]	_	_
3-15	83-84	,	_	_	_	_
3-16	85-87	as	_	_	_	_
3-17	88-92	well	_	_	_	_
3-18	93-95	as	_	_	_	_
3-19	96-99	its	abstract|abstract[9]	giv|new[9]	coref|coref	7-6[45_0]|7-6[45_0]
3-20	100-111	association	abstract[9]	new[9]	_	_
3-21	112-116	with	abstract[9]	new[9]	_	_
3-22	117-127	baroreflex	abstract[9]|abstract[10]|abstract[11]	new[9]|new[10]|new[11]	coref|coref|coref|coref	22-3[160_10]|26-11[197_11]|22-3[160_10]|26-11[197_11]
3-23	128-139	sensitivity	abstract[9]|abstract[10]|abstract[11]	new[9]|new[10]|new[11]	_	_
3-24	140-143	and	abstract[9]|abstract[11]	new[9]|new[11]	_	_
3-25	144-154	activation	abstract[9]|abstract[11]|event[12]	new[9]|new[11]|new[12]	coref	5-24[34_12]
3-26	155-157	of	abstract[9]|abstract[11]|event[12]	new[9]|new[11]|new[12]	_	_
3-27	158-161	the	abstract[9]|abstract[11]|event[12]|abstract[13]	new[9]|new[11]|new[12]|new[13]	_	_
3-28	162-165	CNS	abstract[9]|abstract[11]|event[12]|abstract[13]	new[9]|new[11]|new[12]|new[13]	_	_
3-29	166-167	.	_	_	_	_

#Text=Our findings showed that excessive fructose consumption increased BP and renal SNA , decreased NO bioavailability , and impaired baroreflex response .
4-1	168-171	Our	person|abstract[15]	giv|new[15]	ana|ana	18-7|18-7
4-2	172-180	findings	abstract[15]	new[15]	_	_
4-3	181-187	showed	_	_	_	_
4-4	188-192	that	_	_	_	_
4-5	193-202	excessive	abstract[17]	new[17]	coref	6-19[42_17]
4-6	203-211	fructose	abstract|abstract[17]	giv|new[17]	coref	5-2
4-7	212-223	consumption	abstract[17]	new[17]	_	_
4-8	224-233	increased	abstract	new	none|none	4-8[0_108]|5-4
4-9	234-236	BP	organization	new	coref	5-10
4-10	237-240	and	_	_	_	_
4-11	241-246	renal	abstract|abstract[20]	new|new[20]	coref|coref	5-14[0_20]|5-14[0_20]
4-12	247-250	SNA	abstract[20]	new[20]	_	_
4-13	251-252	,	_	_	_	_
4-14	253-262	decreased	_	_	_	_
4-15	263-265	NO	abstract[21]	new[21]	_	_
4-16	266-281	bioavailability	abstract[21]	new[21]	_	_
4-17	282-283	,	_	_	_	_
4-18	284-287	and	_	_	_	_
4-19	288-296	impaired	_	_	_	_
4-20	297-307	baroreflex	object|abstract[23]	new|new[23]	coref|coref	21-2|21-2
4-21	308-316	response	abstract[23]	new[23]	_	_
4-22	317-318	.	_	_	_	_

#Text=Excessive fructose intake increased serum triglycerides levels and induced BP elevation by stimulating SNA ; however , alleviation of hypertriglyceridemia did not attenuate sympathetic activation and only slightly lowered BP .
5-1	319-328	Excessive	event[25]	new[25]	coref	8-16[64_25]
5-2	329-337	fructose	substance|event[25]	giv|new[25]	coref	6-20
5-3	338-344	intake	event[25]	new[25]	_	_
5-4	345-354	increased	abstract	new	none	8-11
5-5	355-360	serum	abstract|abstract[28]	new|giv[28]	coref|coref|coref|coref	12-16[102_28]|15-28|12-16[102_28]|15-28
5-6	361-374	triglycerides	substance|abstract[28]	new|giv[28]	coref	25-17
5-7	375-381	levels	abstract[28]	giv[28]	_	_
5-8	382-385	and	abstract[28]	giv[28]	_	_
5-9	386-393	induced	abstract[28]|abstract[30]	giv[28]|new[30]	_	_
5-10	394-396	BP	abstract[28]|organization|abstract[30]	giv[28]|giv|new[30]	coref	5-27[35_0]
5-11	397-406	elevation	abstract[28]|abstract[30]	giv[28]|new[30]	_	_
5-12	407-409	by	_	_	_	_
5-13	410-421	stimulating	_	_	_	_
5-14	422-425	SNA	abstract	giv	coref	6-8
5-15	426-427	;	_	_	_	_
5-16	428-435	however	_	_	_	_
5-17	436-437	,	_	_	_	_
5-18	438-449	alleviation	event[32]	new[32]	_	_
5-19	450-452	of	event[32]	new[32]	_	_
5-20	453-473	hypertriglyceridemia	event[32]|abstract	new[32]|new	ana	6-1
5-21	474-477	did	_	_	_	_
5-22	478-481	not	_	_	_	_
5-23	482-491	attenuate	_	_	_	_
5-24	492-503	sympathetic	event[34]	giv[34]	_	_
5-25	504-514	activation	event[34]	giv[34]	_	_
5-26	515-518	and	_	_	_	_
5-27	519-523	only	organization[35]	giv[35]	coref	6-16[40_35]
5-28	524-532	slightly	organization[35]	giv[35]	_	_
5-29	533-540	lowered	organization[35]	giv[35]	_	_
5-30	541-543	BP	organization[35]	giv[35]	_	_
5-31	544-545	.	_	_	_	_

#Text=It was suggested that , mechanistically , SNA played a role in modulating changes in BP due to increased fructose consumption through another unknown pathway .
6-1	546-548	It	abstract	giv	coref	10-12
6-2	549-552	was	_	_	_	_
6-3	553-562	suggested	_	_	_	_
6-4	563-567	that	_	_	_	_
6-5	568-569	,	_	_	_	_
6-6	570-585	mechanistically	_	_	_	_
6-7	586-587	,	_	_	_	_
6-8	588-591	SNA	abstract	giv	coref	15-44[122_0]
6-9	592-598	played	_	_	_	_
6-10	599-600	a	abstract[38]	new[38]	_	_
6-11	601-605	role	abstract[38]	new[38]	_	_
6-12	606-608	in	_	_	_	_
6-13	609-619	modulating	_	_	_	_
6-14	620-627	changes	abstract	new	_	_
6-15	628-630	in	_	_	_	_
6-16	631-633	BP	organization[40]	giv[40]	coref	7-38[0_40]
6-17	634-637	due	organization[40]	giv[40]	_	_
6-18	638-640	to	_	_	_	_
6-19	641-650	increased	abstract[42]	giv[42]	coref	7-9[47_42]
6-20	651-659	fructose	abstract|abstract[42]	giv|giv[42]	coref	7-9
6-21	660-671	consumption	abstract[42]	giv[42]	_	_
6-22	672-679	through	abstract[42]	giv[42]	_	_
6-23	680-687	another	abstract[42]|abstract[43]	giv[42]|new[43]	_	_
6-24	688-695	unknown	abstract[42]|abstract[43]	giv[42]|new[43]	_	_
6-25	696-703	pathway	abstract[42]|abstract[43]	giv[42]|new[43]	_	_
6-26	704-705	.	_	_	_	_

#Text=Epidemiological studies have hinted at a link between fructose consumption and elevated blood pressure . Jalal et al. reported that excess dietary fructose ( ≥74 g/day ) in the form of added sugar was associated with higher BP values in adults in the United States who did not have a history of hypertension .
7-1	706-721	Epidemiological	abstract[44]	new[44]	coref	10-1[82_44]
7-2	722-729	studies	abstract[44]	new[44]	_	_
7-3	730-734	have	_	_	_	_
7-4	735-741	hinted	_	_	_	_
7-5	742-744	at	_	_	_	_
7-6	745-746	a	abstract[45]	giv[45]	_	_
7-7	747-751	link	abstract[45]	giv[45]	_	_
7-8	752-759	between	abstract[45]	giv[45]	_	_
7-9	760-768	fructose	abstract[45]|substance|abstract[47]	giv[45]|giv|giv[47]	coref|coref|coref|coref	5-4|15-5[110_47]|5-4|15-5[110_47]
7-10	769-780	consumption	abstract[45]|abstract[47]	giv[45]|giv[47]	_	_
7-11	781-784	and	abstract[45]	giv[45]	_	_
7-12	785-793	elevated	abstract[45]|abstract[48]	giv[45]|new[48]	_	_
7-13	794-799	blood	abstract[45]|abstract[48]	giv[45]|new[48]	_	_
7-14	800-808	pressure	abstract[45]|abstract[48]	giv[45]|new[48]	_	_
7-15	809-810	.	_	_	_	_
7-16	811-816	Jalal	person	new	_	_
7-17	817-819	et	_	_	_	_
7-18	820-823	al.	_	_	_	_
7-19	824-832	reported	_	_	_	_
7-20	833-837	that	_	_	_	_
7-21	838-844	excess	substance[51]	giv[51]	coref	12-6
7-22	845-852	dietary	abstract|substance[51]	new|giv[51]	_	_
7-23	853-861	fructose	substance[51]	giv[51]	_	_
7-24	862-863	(	_	_	_	_
7-25	864-867	≥74	_	_	_	_
7-26	868-873	g/day	_	_	_	_
7-27	874-875	)	_	_	_	_
7-28	876-878	in	_	_	_	_
7-29	879-882	the	substance[52]	new[52]	_	_
7-30	883-887	form	substance[52]	new[52]	_	_
7-31	888-890	of	substance[52]	new[52]	_	_
7-32	891-896	added	substance[52]|substance[53]	new[52]|new[53]	_	_
7-33	897-902	sugar	substance[52]|substance[53]	new[52]|new[53]	_	_
7-34	903-906	was	_	_	_	_
7-35	907-917	associated	_	_	_	_
7-36	918-922	with	_	_	_	_
7-37	923-929	higher	abstract[55]	new[55]	_	_
7-38	930-932	BP	organization|abstract[55]	giv|new[55]	coref	10-25
7-39	933-939	values	abstract[55]	new[55]	_	_
7-40	940-942	in	abstract[55]	new[55]	_	_
7-41	943-949	adults	abstract[55]|person[56]	new[55]|new[56]	coref	9-6[68_56]
7-42	950-952	in	abstract[55]|person[56]	new[55]|new[56]	_	_
7-43	953-956	the	abstract[55]|person[56]|place[57]	new[55]|new[56]|new[57]	coref	9-8[69_57]
7-44	957-963	United	abstract[55]|person[56]|place[57]	new[55]|new[56]|new[57]	_	_
7-45	964-970	States	abstract[55]|person[56]|place[57]	new[55]|new[56]|new[57]	_	_
7-46	971-974	who	_	_	_	_
7-47	975-978	did	_	_	_	_
7-48	979-982	not	_	_	_	_
7-49	983-987	have	_	_	_	_
7-50	988-989	a	abstract[58]	new[58]	_	_
7-51	990-997	history	abstract[58]	new[58]	_	_
7-52	998-1000	of	abstract[58]	new[58]	_	_
7-53	1001-1013	hypertension	abstract[58]|abstract	new[58]|new	coref	16-7
7-54	1014-1015	.	_	_	_	_

#Text=Similarly , a study of 4867 adolescents found that SBP rose by 2 mmHg following the intake of sugar-sweetened beverages from the lowest to the highest category .
8-1	1016-1025	Similarly	_	_	_	_
8-2	1026-1027	,	_	_	_	_
8-3	1028-1029	a	event[60]	new[60]	coref	9-2[67_60]
8-4	1030-1035	study	event[60]	new[60]	_	_
8-5	1036-1038	of	event[60]	new[60]	_	_
8-6	1039-1043	4867	event[60]|quantity[61]	new[60]|new[61]	_	_
8-7	1044-1055	adolescents	event[60]|quantity[61]	new[60]|new[61]	_	_
8-8	1056-1061	found	_	_	_	_
8-9	1062-1066	that	_	_	_	_
8-10	1067-1070	SBP	quantity	new	coref	9-33
8-11	1071-1075	rose	abstract	new	none	10-24
8-12	1076-1078	by	_	_	_	_
8-13	1079-1080	2	quantity[63]	new[63]	_	_
8-14	1081-1085	mmHg	quantity[63]	new[63]	_	_
8-15	1086-1095	following	_	_	_	_
8-16	1096-1099	the	event[64]	giv[64]	_	_
8-17	1100-1106	intake	event[64]	giv[64]	_	_
8-18	1107-1109	of	event[64]	giv[64]	_	_
8-19	1110-1125	sugar-sweetened	event[64]|substance[65]	giv[64]|new[65]	_	_
8-20	1126-1135	beverages	event[64]|substance[65]	giv[64]|new[65]	_	_
8-21	1136-1140	from	event[64]|substance[65]	giv[64]|new[65]	_	_
8-22	1141-1144	the	event[64]|substance[65]	giv[64]|new[65]	_	_
8-23	1145-1151	lowest	event[64]|substance[65]	giv[64]|new[65]	_	_
8-24	1152-1154	to	_	_	_	_
8-25	1155-1158	the	abstract[66]	new[66]	_	_
8-26	1159-1166	highest	abstract[66]	new[66]	_	_
8-27	1167-1175	category	abstract[66]	new[66]	_	_
8-28	1176-1177	.	_	_	_	_

#Text=In a prospective study involving adults in the United States , Chen et al. found that intake of one less sugar-sweetened beverage per day was associated with a 1.8 mmHg reduction in SBP and a 1.1 mmHg reduction in DBP over 18 months .
9-1	1178-1180	In	_	_	_	_
9-2	1181-1182	a	event[67]	giv[67]	coref	12-2[96_67]
9-3	1183-1194	prospective	event[67]	giv[67]	_	_
9-4	1195-1200	study	event[67]	giv[67]	_	_
9-5	1201-1210	involving	event[67]	giv[67]	_	_
9-6	1211-1217	adults	event[67]|person[68]	giv[67]|giv[68]	_	_
9-7	1218-1220	in	event[67]|person[68]	giv[67]|giv[68]	_	_
9-8	1221-1224	the	event[67]|person[68]|place[69]	giv[67]|giv[68]|giv[69]	_	_
9-9	1225-1231	United	event[67]|person[68]|place[69]	giv[67]|giv[68]|giv[69]	_	_
9-10	1232-1238	States	event[67]|person[68]|place[69]	giv[67]|giv[68]|giv[69]	_	_
9-11	1239-1240	,	_	_	_	_
9-12	1241-1245	Chen	person	new	_	_
9-13	1246-1248	et	_	_	_	_
9-14	1249-1252	al.	_	_	_	_
9-15	1253-1258	found	_	_	_	_
9-16	1259-1263	that	event[71]	new[71]	coref	12-6[98_71]
9-17	1264-1270	intake	event[71]	new[71]	_	_
9-18	1271-1273	of	event[71]	new[71]	_	_
9-19	1274-1277	one	event[71]|substance[72]	new[71]|new[72]	_	_
9-20	1278-1282	less	event[71]|substance[72]	new[71]|new[72]	_	_
9-21	1283-1298	sugar-sweetened	event[71]|substance[72]	new[71]|new[72]	_	_
9-22	1299-1307	beverage	event[71]|substance[72]	new[71]|new[72]	_	_
9-23	1308-1311	per	event[71]|substance[72]	new[71]|new[72]	_	_
9-24	1312-1315	day	event[71]|substance[72]|time	new[71]|new[72]|new	coref	12-27
9-25	1316-1319	was	_	_	_	_
9-26	1320-1330	associated	_	_	_	_
9-27	1331-1335	with	_	_	_	_
9-28	1336-1337	a	abstract[75]	new[75]	_	_
9-29	1338-1341	1.8	abstract[75]	new[75]	_	_
9-30	1342-1346	mmHg	quantity|abstract[75]	new|new[75]	coref	9-37
9-31	1347-1356	reduction	abstract[75]	new[75]	_	_
9-32	1357-1359	in	abstract[75]	new[75]	_	_
9-33	1360-1363	SBP	abstract[75]|quantity	new[75]|giv	_	_
9-34	1364-1367	and	_	_	_	_
9-35	1368-1369	a	abstract[78]	new[78]	_	_
9-36	1370-1373	1.1	abstract[78]	new[78]	_	_
9-37	1374-1378	mmHg	quantity|abstract[78]	giv|new[78]	_	_
9-38	1379-1388	reduction	abstract[78]	new[78]	_	_
9-39	1389-1391	in	abstract[78]	new[78]	_	_
9-40	1392-1395	DBP	abstract[78]|abstract	new[78]|new	_	_
9-41	1396-1400	over	abstract[78]|time[80]	new[78]|new[80]	_	_
9-42	1401-1403	18	abstract[78]|time[80]	new[78]|new[80]	_	_
9-43	1404-1410	months	abstract[78]|time[80]	new[78]|new[80]	_	_
9-44	1411-1412	.	_	_	_	_

#Text=Some animal studies showed that a high-fructose diet was associated with hypertriglyceridemia , hyperinsulinemia , impaired glucose tolerance , insulin resistance , and increased BP and body weight .
10-1	1413-1417	Some	abstract[82]	giv[82]	_	_
10-2	1418-1424	animal	animal|abstract[82]	new|giv[82]	_	_
10-3	1425-1432	studies	abstract[82]	giv[82]	_	_
10-4	1433-1439	showed	_	_	_	_
10-5	1440-1444	that	_	_	_	_
10-6	1445-1446	a	abstract[83]	new[83]	_	_
10-7	1447-1460	high-fructose	abstract[83]	new[83]	_	_
10-8	1461-1465	diet	abstract[83]	new[83]	_	_
10-9	1466-1469	was	_	_	_	_
10-10	1470-1480	associated	_	_	_	_
10-11	1481-1485	with	_	_	_	_
10-12	1486-1506	hypertriglyceridemia	abstract	giv	coref	23-6
10-13	1507-1508	,	_	_	_	_
10-14	1509-1525	hyperinsulinemia	abstract	new	_	_
10-15	1526-1527	,	_	_	_	_
10-16	1528-1536	impaired	abstract[87]	new[87]	_	_
10-17	1537-1544	glucose	substance|abstract[87]	new|new[87]	coref	11-13
10-18	1545-1554	tolerance	abstract[87]	new[87]	_	_
10-19	1555-1556	,	_	_	_	_
10-20	1557-1564	insulin	event|abstract[89]	new|new[89]	_	_
10-21	1565-1575	resistance	abstract[89]	new[89]	_	_
10-22	1576-1577	,	_	_	_	_
10-23	1578-1581	and	_	_	_	_
10-24	1582-1591	increased	abstract	new	none	12-5
10-25	1592-1594	BP	organization	giv	coref	12-16
10-26	1595-1598	and	_	_	_	_
10-27	1599-1603	body	object|abstract[92]	new|new[92]	_	_
10-28	1604-1610	weight	abstract[92]	new[92]	_	_
10-29	1611-1612	.	_	_	_	_

#Text=However , these adverse effects were not indicated with equivalent calories of glucose .
11-1	1613-1620	However	_	_	_	_
11-2	1621-1622	,	_	_	_	_
11-3	1623-1628	these	abstract[93]	new[93]	coref	22-11[163_93]
11-4	1629-1636	adverse	abstract[93]	new[93]	_	_
11-5	1637-1644	effects	abstract[93]	new[93]	_	_
11-6	1645-1649	were	_	_	_	_
11-7	1650-1653	not	_	_	_	_
11-8	1654-1663	indicated	_	_	_	_
11-9	1664-1668	with	_	_	_	_
11-10	1669-1679	equivalent	substance[94]	new[94]	_	_
11-11	1680-1688	calories	substance[94]	new[94]	_	_
11-12	1689-1691	of	substance[94]	new[94]	_	_
11-13	1692-1699	glucose	substance[94]|substance	new[94]|giv	_	_
11-14	1700-1701	.	_	_	_	_

#Text=In this study , increased fructose intake for 0 to 2 days evoked increases in BP levels , and the high BP levels were maintained until day 7 (
12-1	1702-1704	In	_	_	_	_
12-2	1705-1709	this	event[96]	giv[96]	coref	23-1[166_96]
12-3	1710-1715	study	event[96]	giv[96]	_	_
12-4	1716-1717	,	_	_	_	_
12-5	1718-1727	increased	abstract	new	coref	15-1[108_0]
12-6	1728-1736	fructose	substance|event[98]	giv|giv[98]	coref|coref|coref|coref	15-5|27-6[202_98]|15-5|27-6[202_98]
12-7	1737-1743	intake	event[98]	giv[98]	_	_
12-8	1744-1747	for	_	_	_	_
12-9	1748-1749	0	time[99]	new[99]	_	_
12-10	1750-1752	to	time[99]	new[99]	_	_
12-11	1753-1754	2	time[99]	new[99]	_	_
12-12	1755-1759	days	time[99]	new[99]	_	_
12-13	1760-1766	evoked	_	_	_	_
12-14	1767-1776	increases	event[100]	new[100]	_	_
12-15	1777-1779	in	event[100]	new[100]	_	_
12-16	1780-1782	BP	event[100]|organization|abstract[102]	new[100]|giv|giv[102]	coref|coref|coref|coref	12-22|12-20[104_102]|12-22|12-20[104_102]
12-17	1783-1789	levels	event[100]|abstract[102]	new[100]|giv[102]	_	_
12-18	1790-1791	,	_	_	_	_
12-19	1792-1795	and	_	_	_	_
12-20	1796-1799	the	abstract[104]	giv[104]	coref	15-31[120_104]
12-21	1800-1804	high	abstract[104]	giv[104]	_	_
12-22	1805-1807	BP	organization|abstract[104]	giv|giv[104]	coref	18-28
12-23	1808-1814	levels	abstract[104]	giv[104]	_	_
12-24	1815-1819	were	_	_	_	_
12-25	1820-1830	maintained	_	_	_	_
12-26	1831-1836	until	_	_	_	_
12-27	1837-1840	day	time|time[106]	giv|new[106]	_	_
12-28	1841-1842	7	time[106]	new[106]	_	_
12-29	1843-1844	(	_	_	_	_

#Text=Figure 2
13-1	1845-1851	Figure	abstract[107]	new[107]	_	_
13-2	1852-1853	2	abstract[107]	new[107]	_	_

#Text=) .
14-1	1854-1855	)	_	_	_	_
14-2	1856-1857	.	_	_	_	_

#Text=The great increase in fructose consumption in the last decades leads to the rapid accumulation of triglyceride in the Occidental population . Tran et al. reported that serum norepinephrine and triglyceride levels are significantly increased in fructose-fed hypertensive rats , as reflected by high SNA .
15-1	1858-1861	The	abstract[108]	new[108]	_	_
15-2	1862-1867	great	abstract[108]	new[108]	_	_
15-3	1868-1876	increase	abstract[108]	new[108]	_	_
15-4	1877-1879	in	abstract[108]	new[108]	_	_
15-5	1880-1888	fructose	abstract[108]|substance|abstract[110]	new[108]|giv|giv[110]	coref|coref|coref|coref	16-15|16-14[127_110]|16-15|16-14[127_110]
15-6	1889-1900	consumption	abstract[108]|abstract[110]	new[108]|giv[110]	_	_
15-7	1901-1903	in	abstract[108]|abstract[110]	new[108]|giv[110]	_	_
15-8	1904-1907	the	abstract[108]|abstract[110]|time[111]	new[108]|giv[110]|new[111]	_	_
15-9	1908-1912	last	abstract[108]|abstract[110]|time[111]	new[108]|giv[110]|new[111]	_	_
15-10	1913-1920	decades	abstract[108]|abstract[110]|time[111]	new[108]|giv[110]|new[111]	_	_
15-11	1921-1926	leads	_	_	_	_
15-12	1927-1929	to	_	_	_	_
15-13	1930-1933	the	abstract[112]	new[112]	_	_
15-14	1934-1939	rapid	abstract[112]	new[112]	_	_
15-15	1940-1952	accumulation	abstract[112]	new[112]	_	_
15-16	1953-1955	of	abstract[112]	new[112]	_	_
15-17	1956-1968	triglyceride	abstract[112]|substance[113]	new[112]|new[113]	coref	15-31[0_113]
15-18	1969-1971	in	abstract[112]|substance[113]	new[112]|new[113]	_	_
15-19	1972-1975	the	abstract[112]|substance[113]|abstract[115]	new[112]|new[113]|new[115]	_	_
15-20	1976-1986	Occidental	abstract[112]|substance[113]|organization|abstract[115]	new[112]|new[113]|new|new[115]	_	_
15-21	1987-1997	population	abstract[112]|substance[113]|abstract[115]	new[112]|new[113]|new[115]	_	_
15-22	1998-1999	.	_	_	_	_
15-23	2000-2004	Tran	person	new	coref	16-3
15-24	2005-2007	et	_	_	_	_
15-25	2008-2011	al.	_	_	_	_
15-26	2012-2020	reported	_	_	_	_
15-27	2021-2025	that	_	_	_	_
15-28	2026-2031	serum	abstract|substance[118]	giv|new[118]	coref|coref	17-13|17-13
15-29	2032-2046	norepinephrine	substance[118]	new[118]	_	_
15-30	2047-2050	and	_	_	_	_
15-31	2051-2063	triglyceride	substance|abstract[120]	giv|giv[120]	coref|coref|coref|coref	17-11[136_0]|27-10[203_120]|17-11[136_0]|27-10[203_120]
15-32	2064-2070	levels	abstract[120]	giv[120]	_	_
15-33	2071-2074	are	_	_	_	_
15-34	2075-2088	significantly	_	_	_	_
15-35	2089-2098	increased	_	_	_	_
15-36	2099-2101	in	_	_	_	_
15-37	2102-2114	fructose-fed	animal[121]	new[121]	coref	16-11[0_121]
15-38	2115-2127	hypertensive	animal[121]	new[121]	_	_
15-39	2128-2132	rats	animal[121]	new[121]	_	_
15-40	2133-2134	,	_	_	_	_
15-41	2135-2137	as	_	_	_	_
15-42	2138-2147	reflected	_	_	_	_
15-43	2148-2150	by	_	_	_	_
15-44	2151-2155	high	abstract[122]	giv[122]	coref	18-33[0_122]
15-45	2156-2159	SNA	abstract[122]	giv[122]	_	_
15-46	2160-2161	.	_	_	_	_

#Text=According to Tran et al. , hypertension can develop in rats owing to excessive fructose consumption , and the developed hypertension can be treated using a sympatholytic agent called prazosin , which blocks the α1-adrenoreceptors .
16-1	2162-2171	According	_	_	_	_
16-2	2172-2174	to	_	_	_	_
16-3	2175-2179	Tran	person	giv	_	_
16-4	2180-2182	et	_	_	_	_
16-5	2183-2186	al.	_	_	_	_
16-6	2187-2188	,	_	_	_	_
16-7	2189-2201	hypertension	abstract	giv	coref	16-19[128_0]
16-8	2202-2205	can	_	_	_	_
16-9	2206-2213	develop	event	new	coref|none	27-26[208_0]|16-9[0_208]
16-10	2214-2216	in	_	_	_	_
16-11	2217-2221	rats	animal	giv	coref	23-37[177_0]
16-12	2222-2227	owing	_	_	_	_
16-13	2228-2230	to	_	_	_	_
16-14	2231-2240	excessive	abstract[127]	giv[127]	coref	26-7[195_127]
16-15	2241-2249	fructose	substance|abstract[127]	giv|giv[127]	coref	24-9
16-16	2250-2261	consumption	abstract[127]	giv[127]	_	_
16-17	2262-2263	,	_	_	_	_
16-18	2264-2267	and	_	_	_	_
16-19	2268-2271	the	abstract[128]	giv[128]	coref	17-1[0_128]
16-20	2272-2281	developed	abstract[128]	giv[128]	_	_
16-21	2282-2294	hypertension	abstract[128]	giv[128]	_	_
16-22	2295-2298	can	_	_	_	_
16-23	2299-2301	be	_	_	_	_
16-24	2302-2309	treated	_	_	_	_
16-25	2310-2315	using	_	_	_	_
16-26	2316-2317	a	person[129]	new[129]	_	_
16-27	2318-2331	sympatholytic	person[129]	new[129]	_	_
16-28	2332-2337	agent	person[129]	new[129]	_	_
16-29	2338-2344	called	_	_	_	_
16-30	2345-2353	prazosin	substance	new	coref	17-4
16-31	2354-2355	,	_	_	_	_
16-32	2356-2361	which	_	_	_	_
16-33	2362-2368	blocks	_	_	_	_
16-34	2369-2372	the	abstract[131]	new[131]	_	_
16-35	2373-2391	α1-adrenoreceptors	abstract[131]	new[131]	_	_
16-36	2392-2393	.	_	_	_	_

#Text=Hypertension inhibition by prazosin did not reduce the level of triglyceride in serum .
17-1	2394-2406	Hypertension	abstract|abstract[133]	giv|new[133]	_	_
17-2	2407-2417	inhibition	abstract[133]	new[133]	_	_
17-3	2418-2420	by	abstract[133]	new[133]	_	_
17-4	2421-2429	prazosin	abstract[133]|substance	new[133]|giv	_	_
17-5	2430-2433	did	_	_	_	_
17-6	2434-2437	not	_	_	_	_
17-7	2438-2444	reduce	_	_	_	_
17-8	2445-2448	the	abstract[135]	new[135]	coref	18-19[146_135]
17-9	2449-2454	level	abstract[135]	new[135]	_	_
17-10	2455-2457	of	abstract[135]	new[135]	_	_
17-11	2458-2470	triglyceride	abstract[135]|substance[136]	new[135]|giv[136]	coref	18-20[0_136]
17-12	2471-2473	in	abstract[135]|substance[136]	new[135]|giv[136]	_	_
17-13	2474-2479	serum	abstract[135]|substance[136]|substance	new[135]|giv[136]|giv	coref	18-19
17-14	2480-2481	.	_	_	_	_

#Text=Consistent with this previous result , our data showed that the use of a DGAT1 inhibitor for inhibiting serum triglyceride level led to a slight decrease in BP but did not affect SNA (
18-1	2482-2492	Consistent	_	_	_	_
18-2	2493-2497	with	_	_	_	_
18-3	2498-2502	this	abstract[138]	new[138]	_	_
18-4	2503-2511	previous	abstract[138]	new[138]	_	_
18-5	2512-2518	result	abstract[138]	new[138]	_	_
18-6	2519-2520	,	_	_	_	_
18-7	2521-2524	our	person|abstract[140]	giv|new[140]	ana|ana	27-1|27-1
18-8	2525-2529	data	abstract[140]	new[140]	_	_
18-9	2530-2536	showed	_	_	_	_
18-10	2537-2541	that	_	_	_	_
18-11	2542-2545	the	abstract[141]	new[141]	_	_
18-12	2546-2549	use	abstract[141]	new[141]	_	_
18-13	2550-2552	of	abstract[141]	new[141]	_	_
18-14	2553-2554	a	abstract[141]|abstract[143]	new[141]|new[143]	coref	25-9[188_143]
18-15	2555-2560	DGAT1	abstract[141]|abstract|abstract[143]	new[141]|new|new[143]	coref	25-10
18-16	2561-2570	inhibitor	abstract[141]|abstract[143]	new[141]|new[143]	_	_
18-17	2571-2574	for	_	_	_	_
18-18	2575-2585	inhibiting	_	_	_	_
18-19	2586-2591	serum	object|abstract[146]	giv|giv[146]	coref|coref	32-74[236_146]|32-74[236_146]
18-20	2592-2604	triglyceride	substance|abstract[146]	giv|giv[146]	_	_
18-21	2605-2610	level	abstract[146]	giv[146]	_	_
18-22	2611-2614	led	_	_	_	_
18-23	2615-2617	to	_	_	_	_
18-24	2618-2619	a	abstract[147]	new[147]	_	_
18-25	2620-2626	slight	abstract[147]	new[147]	_	_
18-26	2627-2635	decrease	abstract[147]	new[147]	_	_
18-27	2636-2638	in	abstract[147]	new[147]	_	_
18-28	2639-2641	BP	abstract[147]|organization	new[147]|giv	coref	21-19[158_0]
18-29	2642-2645	but	_	_	_	_
18-30	2646-2649	did	_	_	_	_
18-31	2650-2653	not	_	_	_	_
18-32	2654-2660	affect	_	_	_	_
18-33	2661-2664	SNA	abstract	giv	coref	24-21[185_0]
18-34	2665-2666	(	_	_	_	_

#Text=Figure 3
19-1	2667-2673	Figure	abstract[150]	new[150]	_	_
19-2	2674-2675	3	abstract[150]	new[150]	_	_

#Text=) .
20-1	2676-2677	)	_	_	_	_
20-2	2678-2679	.	_	_	_	_

#Text=The baroreflex system is an important mechanism in the regulation of heart rate , sympathetic tone , and consequently BP .
21-1	2680-2683	The	place[152]	new[152]	coref	21-5[153_152]
21-2	2684-2694	baroreflex	place|place[152]	giv|new[152]	coref	27-17
21-3	2695-2701	system	place[152]	new[152]	_	_
21-4	2702-2704	is	_	_	_	_
21-5	2705-2707	an	place[153]	giv[153]	coref	33-16[244_153]
21-6	2708-2717	important	place[153]	giv[153]	_	_
21-7	2718-2727	mechanism	place[153]	giv[153]	_	_
21-8	2728-2730	in	place[153]	giv[153]	_	_
21-9	2731-2734	the	place[153]|abstract[154]	giv[153]|new[154]	_	_
21-10	2735-2745	regulation	place[153]|abstract[154]	giv[153]|new[154]	_	_
21-11	2746-2748	of	place[153]|abstract[154]	giv[153]|new[154]	_	_
21-12	2749-2754	heart	place[153]|abstract[154]|abstract|abstract[156]	giv[153]|new[154]|new|new[156]	_	_
21-13	2755-2759	rate	place[153]|abstract[154]|abstract[156]	giv[153]|new[154]|new[156]	_	_
21-14	2760-2761	,	place[153]|abstract[154]	giv[153]|new[154]	_	_
21-15	2762-2773	sympathetic	place[153]|abstract[154]|abstract[157]	giv[153]|new[154]|new[157]	_	_
21-16	2774-2778	tone	place[153]|abstract[154]|abstract[157]	giv[153]|new[154]|new[157]	_	_
21-17	2779-2780	,	place[153]|abstract[154]	giv[153]|new[154]	_	_
21-18	2781-2784	and	place[153]|abstract[154]	giv[153]|new[154]	_	_
21-19	2785-2797	consequently	place[153]|abstract[154]|organization[158]	giv[153]|new[154]|giv[158]	coref	23-28[174_158]
21-20	2798-2800	BP	place[153]|abstract[154]|organization[158]	giv[153]|new[154]|giv[158]	_	_
21-21	2801-2802	.	_	_	_	_

#Text=Impairment of baroreflex sensitivity is involved in the sympathoexcitatory and sympathoinhibitory effects of metabolic syndromes .
22-1	2803-2813	Impairment	abstract[159]	new[159]	_	_
22-2	2814-2816	of	abstract[159]	new[159]	_	_
22-3	2817-2827	baroreflex	abstract[159]|abstract[160]	new[159]|giv[160]	coref	23-15[170_160]
22-4	2828-2839	sensitivity	abstract[159]|abstract[160]	new[159]|giv[160]	_	_
22-5	2840-2842	is	_	_	_	_
22-6	2843-2851	involved	_	_	_	_
22-7	2852-2854	in	_	_	_	_
22-8	2855-2858	the	abstract[161]	new[161]	_	_
22-9	2859-2877	sympathoexcitatory	abstract[161]	new[161]	_	_
22-10	2878-2881	and	_	_	_	_
22-11	2882-2900	sympathoinhibitory	abstract|abstract[163]	new|giv[163]	_	_
22-12	2901-2908	effects	abstract[163]	giv[163]	_	_
22-13	2909-2911	of	abstract[163]	giv[163]	_	_
22-14	2912-2921	metabolic	abstract[163]|person|abstract[165]	giv[163]|new|new[165]	coref|coref	23-20|23-20
22-15	2922-2931	syndromes	abstract[163]|abstract[165]	giv[163]|new[165]	_	_
22-16	2932-2933	.	_	_	_	_

#Text=A previous study showed that hypertriglyceridemia may be the main contributory factor associated with impaired baroreflex sensitivity during a metabolic syndrome . Soncrant et al. reported that elevated BP was increased by sympathoexcitation in 20 % fructose-induced , salt-sensitive , hypertensive rats .
23-1	2934-2935	A	event[166]	giv[166]	coref	25-4[186_166]
23-2	2936-2944	previous	event[166]	giv[166]	_	_
23-3	2945-2950	study	event[166]	giv[166]	_	_
23-4	2951-2957	showed	_	_	_	_
23-5	2958-2962	that	_	_	_	_
23-6	2963-2983	hypertriglyceridemia	abstract	giv	coref	23-9[169_0]
23-7	2984-2987	may	_	_	_	_
23-8	2988-2990	be	_	_	_	_
23-9	2991-2994	the	abstract[169]	giv[169]	_	_
23-10	2995-2999	main	abstract[169]	giv[169]	_	_
23-11	3000-3012	contributory	abstract|abstract[169]	new|giv[169]	_	_
23-12	3013-3019	factor	abstract[169]	giv[169]	_	_
23-13	3020-3030	associated	_	_	_	_
23-14	3031-3035	with	_	_	_	_
23-15	3036-3044	impaired	abstract[170]	giv[170]	coref	26-11[196_170]
23-16	3045-3055	baroreflex	abstract[170]	giv[170]	_	_
23-17	3056-3067	sensitivity	abstract[170]	giv[170]	_	_
23-18	3068-3074	during	abstract[170]	giv[170]	_	_
23-19	3075-3076	a	abstract[170]|event[172]	giv[170]|new[172]	_	_
23-20	3077-3086	metabolic	abstract[170]|person|event[172]	giv[170]|giv|new[172]	_	_
23-21	3087-3095	syndrome	abstract[170]|event[172]	giv[170]|new[172]	_	_
23-22	3096-3097	.	_	_	_	_
23-23	3098-3106	Soncrant	person	new	_	_
23-24	3107-3109	et	_	_	_	_
23-25	3110-3113	al.	_	_	_	_
23-26	3114-3122	reported	_	_	_	_
23-27	3123-3127	that	_	_	_	_
23-28	3128-3136	elevated	organization[174]	giv[174]	coref	27-29[209_174]
23-29	3137-3139	BP	organization[174]	giv[174]	_	_
23-30	3140-3143	was	_	_	_	_
23-31	3144-3153	increased	_	_	_	_
23-32	3154-3156	by	_	_	_	_
23-33	3157-3175	sympathoexcitation	abstract[175]	new[175]	coref	25-20[0_175]
23-34	3176-3178	in	abstract[175]	new[175]	_	_
23-35	3179-3181	20	abstract[175]|quantity[176]	new[175]|new[176]	ana	24-1[0_176]
23-36	3182-3183	%	abstract[175]|quantity[176]	new[175]|new[176]	_	_
23-37	3184-3200	fructose-induced	animal[177]	giv[177]	coref	25-25[192_177]
23-38	3201-3202	,	animal[177]	giv[177]	_	_
23-39	3203-3217	salt-sensitive	animal[177]	giv[177]	_	_
23-40	3218-3219	,	animal[177]	giv[177]	_	_
23-41	3220-3232	hypertensive	animal[177]	giv[177]	_	_
23-42	3233-3237	rats	animal[177]	giv[177]	_	_
23-43	3238-3239	.	_	_	_	_

#Text=It has been shown that the ingestion of fructose altered the secretion of hormones that regulate energy balance associated with increased SNA .
24-1	3240-3242	It	quantity	giv	_	_
24-2	3243-3246	has	_	_	_	_
24-3	3247-3251	been	_	_	_	_
24-4	3252-3257	shown	_	_	_	_
24-5	3258-3262	that	_	_	_	_
24-6	3263-3266	the	event[179]	new[179]	_	_
24-7	3267-3276	ingestion	event[179]	new[179]	_	_
24-8	3277-3279	of	event[179]	new[179]	_	_
24-9	3280-3288	fructose	event[179]|substance	new[179]|giv	coref	26-7
24-10	3289-3296	altered	_	_	_	_
24-11	3297-3300	the	event[181]	new[181]	_	_
24-12	3301-3310	secretion	event[181]	new[181]	_	_
24-13	3311-3313	of	event[181]	new[181]	_	_
24-14	3314-3322	hormones	event[181]|substance	new[181]|new	_	_
24-15	3323-3327	that	_	_	_	_
24-16	3328-3336	regulate	_	_	_	_
24-17	3337-3343	energy	abstract|abstract[184]	new|new[184]	_	_
24-18	3344-3351	balance	abstract[184]	new[184]	_	_
24-19	3352-3362	associated	_	_	_	_
24-20	3363-3367	with	_	_	_	_
24-21	3368-3377	increased	abstract[185]	giv[185]	coref	27-23[0_185]
24-22	3378-3381	SNA	abstract[185]	giv[185]	_	_
24-23	3382-3383	.	_	_	_	_

#Text=However , in the current study , although a DGAT1 inhibitor was administered orally to block triglycerides production , sympathoexcitation was not inhibited in fructose-fed rats .
25-1	3384-3391	However	_	_	_	_
25-2	3392-3393	,	_	_	_	_
25-3	3394-3396	in	_	_	_	_
25-4	3397-3400	the	event[186]	giv[186]	coref	35-8[254_186]
25-5	3401-3408	current	event[186]	giv[186]	_	_
25-6	3409-3414	study	event[186]	giv[186]	_	_
25-7	3415-3416	,	_	_	_	_
25-8	3417-3425	although	_	_	_	_
25-9	3426-3427	a	abstract[188]	giv[188]	_	_
25-10	3428-3433	DGAT1	abstract|abstract[188]	giv|giv[188]	_	_
25-11	3434-3443	inhibitor	abstract[188]	giv[188]	_	_
25-12	3444-3447	was	_	_	_	_
25-13	3448-3460	administered	_	_	_	_
25-14	3461-3467	orally	_	_	_	_
25-15	3468-3470	to	_	_	_	_
25-16	3471-3476	block	_	_	_	_
25-17	3477-3490	triglycerides	substance|abstract[190]	giv|new[190]	_	_
25-18	3491-3501	production	abstract[190]	new[190]	_	_
25-19	3502-3503	,	_	_	_	_
25-20	3504-3522	sympathoexcitation	abstract	giv	_	_
25-21	3523-3526	was	_	_	_	_
25-22	3527-3530	not	_	_	_	_
25-23	3531-3540	inhibited	_	_	_	_
25-24	3541-3543	in	_	_	_	_
25-25	3544-3556	fructose-fed	animal[192]	giv[192]	_	_
25-26	3557-3561	rats	animal[192]	giv[192]	_	_
25-27	3562-3563	.	_	_	_	_

#Text=Dos Santos et al indicated that fructose consumption similarly reduced both baroreflex sensitivity and activity .
26-1	3564-3567	Dos	person[193]	new[193]	_	_
26-2	3568-3574	Santos	person[193]	new[193]	_	_
26-3	3575-3577	et	_	_	_	_
26-4	3578-3580	al	_	_	_	_
26-5	3581-3590	indicated	_	_	_	_
26-6	3591-3595	that	_	_	_	_
26-7	3596-3604	fructose	substance|abstract[195]	giv|giv[195]	coref|coref	27-6|27-6
26-8	3605-3616	consumption	abstract[195]	giv[195]	_	_
26-9	3617-3626	similarly	_	_	_	_
26-10	3627-3634	reduced	_	_	_	_
26-11	3635-3639	both	abstract[196]|abstract[197]	giv[196]|giv[197]	coref|coref	36-13[0_196]|36-13[0_196]
26-12	3640-3650	baroreflex	abstract[196]|abstract[197]	giv[196]|giv[197]	_	_
26-13	3651-3662	sensitivity	abstract[196]|abstract[197]	giv[196]|giv[197]	_	_
26-14	3663-3666	and	abstract[197]	giv[197]	_	_
26-15	3667-3675	activity	abstract[197]|abstract	giv[197]|new	coref	32-9[215_0]
26-16	3676-3677	.	_	_	_	_

#Text=Our research further indicated that fructose intake may reduce NO levels in the NTS and cause baroreflex dysfunction , which further stimulates SNA and induces the development of high BP (
27-1	3678-3681	Our	person|abstract[200]	giv|new[200]	ana|ana	35-8|35-8
27-2	3682-3690	research	abstract[200]	new[200]	_	_
27-3	3691-3698	further	_	_	_	_
27-4	3699-3708	indicated	_	_	_	_
27-5	3709-3713	that	_	_	_	_
27-6	3714-3722	fructose	substance|event[202]	giv|giv[202]	coref|coref	38-4|38-4
27-7	3723-3729	intake	event[202]	giv[202]	_	_
27-8	3730-3733	may	_	_	_	_
27-9	3734-3740	reduce	_	_	_	_
27-10	3741-3743	NO	abstract[203]	giv[203]	coref	32-5[213_203]
27-11	3744-3750	levels	abstract[203]	giv[203]	_	_
27-12	3751-3753	in	abstract[203]	giv[203]	_	_
27-13	3754-3757	the	abstract[203]|object[204]	giv[203]|giv[204]	_	_
27-14	3758-3761	NTS	abstract[203]|object[204]	giv[203]|giv[204]	_	_
27-15	3762-3765	and	_	_	_	_
27-16	3766-3771	cause	_	_	_	_
27-17	3772-3782	baroreflex	abstract|abstract[206]	giv|new[206]	_	_
27-18	3783-3794	dysfunction	abstract[206]	new[206]	_	_
27-19	3795-3796	,	_	_	_	_
27-20	3797-3802	which	_	_	_	_
27-21	3803-3810	further	_	_	_	_
27-22	3811-3821	stimulates	_	_	_	_
27-23	3822-3825	SNA	abstract	giv	_	_
27-24	3826-3829	and	_	_	_	_
27-25	3830-3837	induces	_	_	_	_
27-26	3838-3841	the	event[208]	new[208]	_	_
27-27	3842-3853	development	event[208]	new[208]	_	_
27-28	3854-3856	of	event[208]	new[208]	_	_
27-29	3857-3861	high	event[208]|organization[209]	new[208]|giv[209]	coref	32-75[0_209]
27-30	3862-3864	BP	event[208]|organization[209]	new[208]|giv[209]	_	_
27-31	3865-3866	(	_	_	_	_

#Text=Figure 4
28-1	3867-3873	Figure	abstract[210]	new[210]	_	_
28-2	3874-3875	4	abstract[210]	new[210]	_	_

#Text=and
29-1	3876-3879	and	_	_	_	_

#Text=Figure 5
30-1	3880-3886	Figure	abstract[211]	new[211]	_	_
30-2	3887-3888	5	abstract[211]	new[211]	_	_

#Text=) .
31-1	3889-3890	)	_	_	_	_
31-2	3891-3892	.	_	_	_	_

#Text=Generally , anesthetics affect the basal levels of sympathetic nerve activity to regulate blood pressure , which plays an important role in controlling cardiovascular function . Sun et al. indicated that anesthesia attenuated the excitatory response of RSNA and HR to anaphylactic hypotension , while these excitatory responses were attenuated by anesthetics in the order ketamine-xylazine > urethane = pentobarbital . Bencze et al. found that pentobarbital anesthesia had a modest influence on the BP level and its maintenance by the above vasoactive systems .
32-1	3893-3902	Generally	_	_	_	_
32-2	3903-3904	,	_	_	_	_
32-3	3905-3916	anesthetics	substance	new	coref	32-52[227_0]
32-4	3917-3923	affect	_	_	_	_
32-5	3924-3927	the	abstract[213]	giv[213]	_	_
32-6	3928-3933	basal	abstract[213]	giv[213]	_	_
32-7	3934-3940	levels	abstract[213]	giv[213]	_	_
32-8	3941-3943	of	abstract[213]	giv[213]	_	_
32-9	3944-3955	sympathetic	abstract[213]|abstract[215]	giv[213]|giv[215]	coref	34-3[248_215]
32-10	3956-3961	nerve	abstract[213]|abstract|abstract[215]	giv[213]|new|giv[215]	coref	34-4
32-11	3962-3970	activity	abstract[213]|abstract[215]	giv[213]|giv[215]	_	_
32-12	3971-3973	to	_	_	_	_
32-13	3974-3982	regulate	_	_	_	_
32-14	3983-3988	blood	abstract[216]	new[216]	_	_
32-15	3989-3997	pressure	abstract[216]	new[216]	_	_
32-16	3998-3999	,	_	_	_	_
32-17	4000-4005	which	_	_	_	_
32-18	4006-4011	plays	_	_	_	_
32-19	4012-4014	an	abstract[217]	new[217]	_	_
32-20	4015-4024	important	abstract[217]	new[217]	_	_
32-21	4025-4029	role	abstract[217]	new[217]	_	_
32-22	4030-4032	in	_	_	_	_
32-23	4033-4044	controlling	_	_	_	_
32-24	4045-4059	cardiovascular	abstract|abstract[219]	new|new[219]	ana|coref|ana|coref	32-78[0_219]|34-7|32-78[0_219]|34-7
32-25	4060-4068	function	abstract[219]	new[219]	_	_
32-26	4069-4070	.	_	_	_	_
32-27	4071-4074	Sun	person	new	_	_
32-28	4075-4077	et	_	_	_	_
32-29	4078-4081	al.	_	_	_	_
32-30	4082-4091	indicated	_	_	_	_
32-31	4092-4096	that	_	_	_	_
32-32	4097-4107	anesthesia	abstract	new	coref	32-67[233_0]
32-33	4108-4118	attenuated	_	_	_	_
32-34	4119-4122	the	abstract[222]	new[222]	_	_
32-35	4123-4133	excitatory	abstract[222]	new[222]	_	_
32-36	4134-4142	response	abstract[222]	new[222]	_	_
32-37	4143-4145	of	abstract[222]	new[222]	_	_
32-38	4146-4150	RSNA	abstract[222]|abstract	new[222]|new	coref	36-10
32-39	4151-4154	and	abstract[222]	new[222]	_	_
32-40	4155-4157	HR	abstract[222]|time[224]	new[222]|new[224]	_	_
32-41	4158-4160	to	abstract[222]|time[224]	new[222]|new[224]	_	_
32-42	4161-4173	anaphylactic	abstract[222]|time[224]|abstract[225]	new[222]|new[224]|new[225]	_	_
32-43	4174-4185	hypotension	abstract[222]|time[224]|abstract[225]	new[222]|new[224]|new[225]	_	_
32-44	4186-4187	,	_	_	_	_
32-45	4188-4193	while	_	_	_	_
32-46	4194-4199	these	abstract[226]	new[226]	_	_
32-47	4200-4210	excitatory	abstract[226]	new[226]	_	_
32-48	4211-4220	responses	abstract[226]	new[226]	_	_
32-49	4221-4225	were	_	_	_	_
32-50	4226-4236	attenuated	_	_	_	_
32-51	4237-4239	by	_	_	_	_
32-52	4240-4251	anesthetics	substance[227]	giv[227]	coref	33-4[0_227]
32-53	4252-4254	in	substance[227]	giv[227]	_	_
32-54	4255-4258	the	substance[227]|abstract[228]|substance[229]	giv[227]|new[228]|new[229]	_	_
32-55	4259-4264	order	substance[227]|abstract[228]|substance[229]	giv[227]|new[228]|new[229]	_	_
32-56	4265-4282	ketamine-xylazine	substance[227]|abstract[228]|substance[229]	giv[227]|new[228]|new[229]	_	_
32-57	4283-4284	>	substance[227]|abstract[228]|substance[229]	giv[227]|new[228]|new[229]	_	_
32-58	4285-4293	urethane	substance[227]|abstract[228]|substance[229]|substance	giv[227]|new[228]|new[229]|new	_	_
32-59	4294-4295	=	_	_	_	_
32-60	4296-4309	pentobarbital	substance	new	_	_
32-61	4310-4311	.	_	_	_	_
32-62	4312-4318	Bencze	person	new	_	_
32-63	4319-4321	et	_	_	_	_
32-64	4322-4325	al.	_	_	_	_
32-65	4326-4331	found	_	_	_	_
32-66	4332-4336	that	_	_	_	_
32-67	4337-4350	pentobarbital	abstract[233]	giv[233]	_	_
32-68	4351-4361	anesthesia	abstract[233]	giv[233]	_	_
32-69	4362-4365	had	_	_	_	_
32-70	4366-4367	a	abstract[234]	new[234]	_	_
32-71	4368-4374	modest	abstract[234]	new[234]	_	_
32-72	4375-4384	influence	abstract[234]	new[234]	_	_
32-73	4385-4387	on	abstract[234]	new[234]	_	_
32-74	4388-4391	the	abstract[234]|abstract[236]	new[234]|giv[236]	_	_
32-75	4392-4394	BP	abstract[234]|organization|abstract[236]	new[234]|giv|giv[236]	coref	36-5
32-76	4395-4400	level	abstract[234]|abstract[236]	new[234]|giv[236]	_	_
32-77	4401-4404	and	abstract[234]	new[234]	_	_
32-78	4405-4408	its	abstract[234]|abstract|abstract[238]	new[234]|giv|new[238]	coref|coref	34-7[250_0]|34-7[250_0]
32-79	4409-4420	maintenance	abstract[234]|abstract[238]	new[234]|new[238]	_	_
32-80	4421-4423	by	abstract[234]|abstract[238]	new[234]|new[238]	_	_
32-81	4424-4427	the	abstract[234]|abstract[238]|abstract[239]	new[234]|new[238]|new[239]	_	_
32-82	4428-4433	above	abstract[234]|abstract[238]|abstract[239]	new[234]|new[238]|new[239]	_	_
32-83	4434-4444	vasoactive	abstract[234]|abstract[238]|abstract[239]	new[234]|new[238]|new[239]	_	_
32-84	4445-4452	systems	abstract[234]|abstract[238]|abstract[239]	new[234]|new[238]|new[239]	_	_
32-85	4453-4454	.	_	_	_	_

#Text=In addition , anesthetics may inhibit the primary area in the baroreceptor reflex pathway of the central nervous system , resulting in attenuation of the baroreceptor reflex .
33-1	4455-4457	In	_	_	_	_
33-2	4458-4466	addition	_	_	_	_
33-3	4467-4468	,	_	_	_	_
33-4	4469-4480	anesthetics	substance	giv	_	_
33-5	4481-4484	may	_	_	_	_
33-6	4485-4492	inhibit	_	_	_	_
33-7	4493-4496	the	abstract[241]	new[241]	_	_
33-8	4497-4504	primary	abstract[241]	new[241]	_	_
33-9	4505-4509	area	abstract[241]	new[241]	_	_
33-10	4510-4512	in	abstract[241]	new[241]	_	_
33-11	4513-4516	the	abstract[241]|abstract[243]	new[241]|new[243]	_	_
33-12	4517-4529	baroreceptor	abstract[241]|abstract[243]	new[241]|new[243]	_	_
33-13	4530-4536	reflex	abstract[241]|place|abstract[243]	new[241]|new|new[243]	coref	10-24
33-14	4537-4544	pathway	abstract[241]|abstract[243]	new[241]|new[243]	_	_
33-15	4545-4547	of	abstract[241]|abstract[243]	new[241]|new[243]	_	_
33-16	4548-4551	the	abstract[241]|abstract[243]|place[244]	new[241]|new[243]|giv[244]	_	_
33-17	4552-4559	central	abstract[241]|abstract[243]|place[244]	new[241]|new[243]|giv[244]	_	_
33-18	4560-4567	nervous	abstract[241]|abstract[243]|place[244]	new[241]|new[243]|giv[244]	_	_
33-19	4568-4574	system	abstract[241]|abstract[243]|place[244]	new[241]|new[243]|giv[244]	_	_
33-20	4575-4576	,	_	_	_	_
33-21	4577-4586	resulting	_	_	_	_
33-22	4587-4589	in	_	_	_	_
33-23	4590-4601	attenuation	event[245]	new[245]	_	_
33-24	4602-4604	of	event[245]	new[245]	_	_
33-25	4605-4608	the	event[245]|place[246]	new[245]|giv[246]	_	_
33-26	4609-4621	baroreceptor	event[245]|place[246]	new[245]|giv[246]	_	_
33-27	4622-4628	reflex	event[245]|place[246]	new[245]|giv[246]	_	_
33-28	4629-4630	.	_	_	_	_

#Text=Therefore , sympathetic nerve activity and cardiovascular function may be affected by the anesthetic .
34-1	4631-4640	Therefore	_	_	_	_
34-2	4641-4642	,	_	_	_	_
34-3	4643-4654	sympathetic	abstract[248]	giv[248]	_	_
34-4	4655-4660	nerve	abstract|abstract[248]	giv|giv[248]	_	_
34-5	4661-4669	activity	abstract[248]	giv[248]	_	_
34-6	4670-4673	and	_	_	_	_
34-7	4674-4688	cardiovascular	abstract|abstract[250]	giv|giv[250]	_	_
34-8	4689-4697	function	abstract[250]	giv[250]	_	_
34-9	4698-4701	may	_	_	_	_
34-10	4702-4704	be	_	_	_	_
34-11	4705-4713	affected	_	_	_	_
34-12	4714-4716	by	_	_	_	_
34-13	4717-4720	the	substance[251]	new[251]	coref	36-18[261_251]
34-14	4721-4731	anesthetic	substance[251]	new[251]	_	_
34-15	4732-4733	.	_	_	_	_

#Text=However , there were some limitations to our study .
35-1	4734-4741	However	_	_	_	_
35-2	4742-4743	,	_	_	_	_
35-3	4744-4749	there	_	_	_	_
35-4	4750-4754	were	_	_	_	_
35-5	4755-4759	some	abstract[252]	new[252]	_	_
35-6	4760-4771	limitations	abstract[252]	new[252]	_	_
35-7	4772-4774	to	abstract[252]	new[252]	_	_
35-8	4775-4778	our	abstract[252]|person|event[254]	new[252]|giv|giv[254]	ana|coref|ana|coref	36-3|37-10[265_254]|36-3|37-10[265_254]
35-9	4779-4784	study	abstract[252]|event[254]	new[252]|giv[254]	_	_
35-10	4785-4786	.	_	_	_	_

#Text=First , we measured BP during consciousness , whereas RSNA and baroreflex sensitivity measurements were performed under the anesthetic .
36-1	4787-4792	First	_	_	_	_
36-2	4793-4794	,	_	_	_	_
36-3	4795-4797	we	person	giv	ana	37-3
36-4	4798-4806	measured	_	_	_	_
36-5	4807-4809	BP	abstract	giv	_	_
36-6	4810-4816	during	_	_	_	_
36-7	4817-4830	consciousness	abstract	new	_	_
36-8	4831-4832	,	_	_	_	_
36-9	4833-4840	whereas	_	_	_	_
36-10	4841-4845	RSNA	abstract	giv	_	_
36-11	4846-4849	and	_	_	_	_
36-12	4850-4860	baroreflex	_	_	_	_
36-13	4861-4872	sensitivity	abstract|abstract[260]	giv|new[260]	_	_
36-14	4873-4885	measurements	abstract[260]	new[260]	_	_
36-15	4886-4890	were	_	_	_	_
36-16	4891-4900	performed	_	_	_	_
36-17	4901-4906	under	_	_	_	_
36-18	4907-4910	the	abstract[261]	giv[261]	_	_
36-19	4911-4921	anesthetic	abstract[261]	giv[261]	_	_
36-20	4922-4923	.	_	_	_	_

#Text=Second , our sample size was relatively small and the study used nonparametric methods for analysis .
37-1	4924-4930	Second	_	_	_	_
37-2	4931-4932	,	_	_	_	_
37-3	4933-4936	our	person|abstract[264]	giv|new[264]	_	_
37-4	4937-4943	sample	object|abstract[264]	new|new[264]	_	_
37-5	4944-4948	size	abstract[264]	new[264]	_	_
37-6	4949-4952	was	_	_	_	_
37-7	4953-4963	relatively	_	_	_	_
37-8	4964-4969	small	_	_	_	_
37-9	4970-4973	and	_	_	_	_
37-10	4974-4977	the	event[265]	giv[265]	_	_
37-11	4978-4983	study	event[265]	giv[265]	_	_
37-12	4984-4988	used	_	_	_	_
37-13	4989-5002	nonparametric	abstract[266]	new[266]	_	_
37-14	5003-5010	methods	abstract[266]	new[266]	_	_
37-15	5011-5014	for	_	_	_	_
37-16	5015-5023	analysis	abstract	new	_	_
37-17	5024-5025	.	_	_	_	_

#Text=Third , the fructose group was used as the control group only on day 0 .
38-1	5026-5031	Third	_	_	_	_
38-2	5032-5033	,	_	_	_	_
38-3	5034-5037	the	substance[269]	new[269]	_	_
38-4	5038-5046	fructose	abstract|substance[269]	giv|new[269]	_	_
38-5	5047-5052	group	substance[269]	new[269]	_	_
38-6	5053-5056	was	_	_	_	_
38-7	5057-5061	used	_	_	_	_
38-8	5062-5064	as	_	_	_	_
38-9	5065-5068	the	_	_	_	_
38-10	5069-5076	control	abstract	new	_	_
38-11	5077-5082	group	_	_	_	_
38-12	5083-5087	only	time[271]	new[271]	_	_
38-13	5088-5090	on	time[271]	new[271]	_	_
38-14	5091-5094	day	time[271]	new[271]	_	_
38-15	5095-5096	0	time[271]	new[271]	_	_
38-16	5097-5098	.	_	_	_	_
